The Role of the Tear Film in Refraction: Quantitative Evaluation Before and After Rexon-Eye Therapy

The aim of this study was to assess the effect of Rexon-Eye therapy, based on quantum molecular resonance (QMR) technology, optical parameters, tear film stability, and patients' subjective symptoms.

A total of 30 patients (20 women, mean age 64.9 years; 10 men, mean age 64.6 years) diagnosed with dry eye syndrome were included in the study. Common systemic comorbidities were recorded, most frequently arterial hypertension, hypercholesterolemia, thyroid disorders, type 2 diabetes mellitus, and hyperuricemia. Each patient underwent four treatment sessions (once weekly for 20 minutes) according to the manufacturer's recommended protocol. Objective parameters - including objective scatter index (OSI), modulation transfer function cutoff (MTF cutoff), potential visual acuity (PVA), and vision break-up time (VBUT) - were assessed using the HD Analyzer before therapy and again 1 to 3 months after treatment completion. Subjective symptoms were evaluated using the standardized Ocular Surface Disease Index (OSDI) questionnaire.

No statistically significant changes were observed in OSI, MTF cutoff, or PVA. VBUT remained unchanged. By contrast, OSDI scores improved both statistically and clinically significantly.

QMR therapy with the Rexon-Eye device led to significant improvement in subjective symptoms, while objective optical quality parameters showed no statistically significant changes. QMR therapy appears to be a safe and well-tolerated method that may expand therapeutic options in clinical practice.